Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 05/07/24
Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024GlobeNewsWire • 05/01/24
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic RetinopathyGlobeNewsWire • 04/18/24
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEOGlobeNewsWire • 04/15/24
Down -17.88% in 4 Weeks, Here's Why Ocular Therapeutix (OCUL) Looks Ripe for a TurnaroundZacks Investment Research • 04/09/24
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of BiometricsGlobeNewsWire • 04/09/24
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual MeetingGlobeNewsWire • 04/06/24
Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)GlobeNewsWire • 03/26/24
Wall Street Analysts Think Ocular Therapeutix (OCUL) Could Surge 34.74%: Read This Before Placing a BetZacks Investment Research • 03/12/24
Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024GlobeNewsWire • 03/05/24
Are You Looking for a Top Momentum Pick? Why Ocular Therapeutix (OCUL) is a Great ChoiceZacks Investment Research • 02/26/24
Ocular Therapeutix (OCUL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 02/26/24
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy OfficerGlobeNewsWire • 02/22/24